tirzepatide or semaglutide better for weight loss vs Tirzepatide: Which Is Loss? Tirzepatide vs Semaglutide 2026: 22%

However, absence of evidence is not evidence of absence. The sample sizes were small, and rare side effects (or ones that occur with prolonged use) could easily have been missed

Interestingly, the SURMOUNT-5 trial found that gastrointestinal adverse events causing treatment discontinuation occurred in 5.6% of semaglutide users compared to only 2.7% of tirzepatide users

Market Trends Around Small-Format Products The appeal of small formats to potential clients is verified by the frequency that they express interest in making additional purchases

However, the company also appreciates that not everyone will be satisfied with the results